Robert J. Sheppard
AstraZeneca (Brazil)(BR)AstraZeneca (Sweden)(SE)
Publications by Year
Research Areas
Protein Degradation and Inhibitors, Ubiquitin and proteasome pathways, RNA and protein synthesis mechanisms, Multiple Myeloma Research and Treatments, Chemical Synthesis and Analysis
Most-Cited Works
- → A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response(2012)940 cited
- → Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation(2015)734 cited
- → Nanomolar Inhibitors of Staphylococcus aureus Methionyl tRNA Synthetase with Potent Antibacterial Activity against Gram-Positive Pathogens(2002)102 cited
- → 1,3-Dimethyl Benzimidazolones Are Potent, Selective Inhibitors of the BRPF1 Bromodomain(2014)89 cited
- → Structure-Based Optimization of Naphthyridones into Potent ATAD2 Bromodomain Inhibitors(2015)83 cited
- → Fragment-Based Discovery of Low-Micromolar ATAD2 Bromodomain Inhibitors(2015)79 cited
- → A Chemical Probe for the ATAD2 Bromodomain(2016)75 cited
- → Mechanistic Insights into the Inhibition of Serine Proteases by Monocyclic Lactams,(1999)72 cited
- → Aminoalkyl adenylate and aminoacyl sulfamate intermediate analogues differing greatly in affinity for their cognate Staphylococcus aureus aminoacyl tRNA synthetases(2000)67 cited
- → GSK6853, a Chemical Probe for Inhibition of the BRPF1 Bromodomain(2016)65 cited